📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Astec LifeSciences Q3FY26: Revenue Up 31% YoY, Returns to Positive EBITDA of Rs 4.8 Cr
Astec LifeSciences reported a significant recovery in Q3FY26, with total income rising 31% YoY to Rs 125.5 crore. The company achieved a positive EBITDA of Rs 4.8 crore, a notable turnaround from the Rs 3.8 crore loss in the same quarter last year. While the company still reported a net loss of Rs 15.7 crore, it is a substantial reduction from the Rs 40.4 crore loss in Q3FY25. Growth was primarily driven by higher enterprise volumes and improved offtake in the Contract Development and Manufacturing Organization (CDMO) segment.
Key Highlights
Total income grew 31% YoY to Rs 125.5 crore in Q3FY26 compared to Rs 95.8 crore in Q3FY25.
EBITDA turned positive at Rs 4.8 crore in Q3FY26 versus a loss of Rs 3.8 crore in the previous year.
Net loss narrowed significantly to Rs 15.7 crore from a loss of Rs 40.4 crore in the same period last year.
Enterprise segment revenue increased by 36.7% YoY, while Contract Manufacturing grew by 29.7% YoY.
Domestic sales witnessed a sharp growth of 55.9% YoY, reaching Rs 37.9 crore.
💼 Action for Investors
The return to positive EBITDA and narrowing losses suggest a recovery phase; investors should monitor the sustainability of CDMO volumes and margin improvement in upcoming quarters.
Astec LifeSciences Q3 Net Loss Narrows to ₹15.7 Cr; Revenue Up 33% YoY
Astec LifeSciences reported a significant narrowing of its net loss to ₹15.72 crore in Q3 FY26, compared to a ₹40.40 crore loss in the same period last year. Revenue from operations grew by 32.9% year-on-year to ₹124.72 crore, showing signs of operational recovery. The company also announced a leadership transition, with CFO Mugdha Amol Khare resigning and Deepak Jawaharlal Ochani, a Godrej Agrovet veteran, appointed as the new CFO effective April 2026. The balance sheet has strengthened, with the debt-equity ratio improving to 1.08 from 2.06 a year ago.
Key Highlights
Revenue from operations increased 32.9% YoY to ₹124.72 crore in Q3 FY26.
Net loss narrowed to ₹15.72 crore from ₹40.40 crore in the previous year's corresponding quarter.
Debt-to-Equity ratio improved significantly to 1.08 compared to 2.06 in December 2024.
Exceptional item of ₹2.09 crore recognized due to the financial impact of new Government Labour Codes.
CFO transition: Deepak Ochani to succeed Mugdha Khare effective April 1, 2026.
💼 Action for Investors
Investors should monitor if the narrowing losses and revenue growth translate into a full turnaround in the coming quarters. The appointment of a Godrej group veteran as CFO suggests a focus on financial stability, but the company remains in a loss-making position.